Kolmonen Promotion Playoffs stats & predictions

Making Informed Decisions: A Bettor's Guide

Making informed decisions is key to successful betting. By combining expert predictions with personal analysis, bettors can enhance their chances of making profitable bets. It's important to stay disciplined and not let emotions drive your betting strategy.

Tips for Informed Betting Decisions

1000 copies/mL despite adherence support measures 39: History or known exposure during previous year prior enrolment including injection drug use or receipt blood transfusion(s) 40: Diagnosis during previous year prior enrolment including tuberculosis active TB disease including pulmonary TB disease or extrapulmonary TB disease including meningeal TB disease diagnosed using clinical criteria microbiological evidence including acid-fast bacilli smear positive sputum culture positive GeneXpert MTB/RIF positive cerebrospinal fluid culture positive GeneXpert MTB/RIF positive other specimen culture positive GeneXpert MTB/RIF positive malignancy including Kaposi’s sarcoma cervical cancer Hodgkin’s lymphoma non-Hodgkin’s lymphoma other cancer active hepatitis B infection defined as plasma HBV DNA >2000 IU/mL active hepatitis C infection defined as plasma HCV RNA >15 IU/mL chronic kidney disease defined as estimated glomerular filtration rate ≤60 mL/min/1.73 m2 pregnancy lactation breast feeding 41: ### Recruitment strategy 42: Participants will be recruited from existing HIV clinics participating in other studies conducted by our research group. 43: ### Randomization procedure 44: Eligible participants will be randomized into one of two arms using block randomization method via computer generated random numbers stratified by site using variable block size ranging from four participants per block up until eight participants per block. 45: ### Study objectives 46: Primary objective 47: To compare virological suppression rates between CAB-LA administered every eight weeks compared with oral ART administered daily over a period of one year. 48: Secondary objectives 49: To determine safety profiles associated with use of CAB-LA administered every eight weeks compared with oral ART administered daily over one year. 50: To determine side effect profiles associated with use of CAB-LA administered every eight weeks compared with oral ART administered daily over one year. 51: ### Study assessments 52: Demographic characteristics including age gender height weight ethnicity employment status educational level monthly income marital status housing type insurance status alcohol use smoking status illicit drug use sexual orientation number sexual partners per week condom use per week history substance abuse mental health history family history medical history social history obstetric/gynaecological history urological history sexual health history psychiatric history medication allergy history immunization history prior surgical procedures current medications laboratory investigations clinical assessments adverse events clinical laboratory investigations baseline screening laboratory investigations baseline screening CD4 cell count plasma viral load pregnancy test pregnancy test haemoglobin Hb plasma glucose liver function tests alanine transaminase ALT aspartate transaminase AST serum creatinine creatinine clearance eGFR urinalysis hepatitis B surface antigen HBsAg hepatitis B core antibody anti-HBc hepatitis C antibody anti-HCV HIV viral load CD4 cell count urine pregnancy test urine pregnancy test haemoglobin Hb plasma glucose liver function tests alanine transaminase ALT aspartate transaminase AST serum creatinine creatinine clearance eGFR urinalysis pregnancy test urine pregnancy test haemoglobin Hb plasma glucose liver function tests alanine transaminase ALT aspartate transaminase AST serum creatinine creatinine clearance eGFR urinalysis adverse events injection site reaction injection site reaction injection site reaction adverse events injection site reaction injection site reaction injection site reaction adverse events 53: ### Data collection tools/methods/equipment/technology platforms used 54: Demographic characteristics including age gender height weight ethnicity employment status educational level monthly income marital status housing type insurance status alcohol use smoking status illicit drug use sexual orientation number sexual partners per week condom use per week history substance abuse mental health history family history medical history social history obstetric/gynaecological history urological history sexual health history psychiatric history medication allergy history immunization history prior surgical procedures current medications laboratory investigations clinical assessments adverse events clinical laboratory investigations baseline screening laboratory investigations baseline screening CD4 cell count plasma viral load pregnancy test pregnancy test haemoglobin Hb plasma glucose liver function tests alanine transaminase ALT aspartate transaminase AST serum creatinine creatinine clearance eGFR urinalysis hepatitis B surface antigen HBsAg hepatitis B core antibody anti-HBc hepatitis C antibody anti-HCV HIV viral load CD4 cell count urine pregnancy test urine pregnancy test haemoglobin Hb plasma glucose liver function tests alanine transaminase ALT aspartate transaminase AST serum creatinine creatinine clearance eGFR urinalysis pregnancy test urine pregnancy test haemoglobin Hb plasma glucose liver function tests alanine transaminase ALT aspartate transaminase AST serum creatinine creatinine clearance eGFR urinalysis adverse events injection site reaction injection site reaction injection site reaction adverse events injection site reaction injection site reaction injection site reaction adverse events 55: ### Adverse event reporting procedure/adverse event follow-up procedure/adverse event causality assessment procedure/adverse event severity grading procedure/adverse event outcome follow-up procedure/specific management plan/procedures for unblinding due adverse event reporting procedures/withdrawal criteria due adverse event reporting procedures/adverse event reporting forms/adverse event reporting timelines/adverse event reporting contacts/criteria considered serious adverse events/criteria considered severe adverse events/criteria considered related adverse events/procedures considered life-threatening serious adverse events/procedures considered medically significant serious adverse events/procedures considered hospitalization required serious adverse events/procedures considered disability permanent serious adverse events/procedures considered congenital anomaly serious adverse events/procedures considered death serious adverse events/procedures considered required intervention prevention serious adverse events/procedures considered required prolonged duration serious adverse events/procedures considered required medical/surgical intervention serious adverse events/procedures considered medically significant special follow-up investigation serious adverse events/specific actions taken due life-threatening serious adverse events/specific actions taken due medically significant serious adverse events/specific actions taken due hospitalization required serious adverse